No Data
No Data
Blueprint Medicines Analyst Ratings
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Express News | Reported Saturday, Blueprint Medicines Showcases AYVAKIT'S Survival Benefits And Disease-Modifying Effects In Advanced Systemic Mastocytosis At ASH 2024
Blueprint Medicines: A Promising Investment With Innovative Treatments and Strong Financial Position
Insider Sale: CHIEF OPERATING OFFICER of $BPMC (BPMC) Sells 2,274 Shares
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump